Data gathered: July 4
AI Stock Analysis - Anavex Life Sciences (AVXL)
Analysis generated June 18, 2025. Powered by Chat GPT.
Anavex Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel drugs for the treatment of central nervous system diseases, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. The company leverages its proprietary SIGMAR1 platform to harness the therapeutic potential of small molecules. Anavex's lead drug candidate, ANAVEX®2-73, has shown promising results in clinical trials, making the company a compelling player in the biotech industry.
Stock Alerts - Anavex Life Sciences (AVXL)
 |
Anavex Life Sciences | July 2 Price is up by 7.9% in the last 24h. |
|
Anavex Life Sciences | June 16 Price is up by 7.1% in the last 24h. |
|
Anavex Life Sciences | May 20 Price is down by -8.3% in the last 24h. |
|
Anavex Life Sciences | May 6 Price is down by -7.2% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Anavex Life Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | N/A | Sign up | Sign up | Sign up |
| Google Trends | 54 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,567 | Sign up | Sign up | Sign up |
| Reddit Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 552 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 23,123 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,118 | Sign up | Sign up | Sign up |
| Twitter Mentions | 83 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
About Anavex Life Sciences
Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and is focusing on rare diseases with no available therapy (Rett syndrome) as well as neurodegenerative diseases that are on the rise due to aging populations (Parkinson's Disease and Alzheimer's Disease) More about us.
| Price | $10.79 |
| Target Price | Sign up |
| Volume | 798,550 |
| Market Cap | $921M |
| Year Range | $5.24 - $13.46 |
| Dividend Yield | 0% |
| Industry | Biotechnology |
In the news
Anavex Life Sciences Corp.(NasdaqGS: AVXL) dropped from Russell Microcap Value IndexJune 29 - Finnhub |
|
Anavex Life Sciences Corp.(NasdaqGS: AVXL) dropped from Russell 3000E Value IndexJune 29 - Finnhub |
|
Anavex Life Sciences Corp.(NasdaqGS: AVXL) dropped from Russell 2000 Value IndexJune 29 - Finnhub |
|
Anavex Life Sciences Corp.(NasdaqGS: AVXL) dropped from Russell 3000 Value IndexJune 29 - Finnhub |
|
Anavex Life Sciences Corp.(NasdaqGS: AVXL) dropped from Russell 2500 Value IndexJune 29 - Finnhub |
|
Anavex Life Sciences Corp.(NasdaqGS: AVXL) dropped from Russell Small Cap Comp Value IndexJune 29 - Finnhub |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -11M | 0 | -0.132 |
| Q4 '24 | 0 | 0 | 0 | -12M | -13M | -0.140 |
| Q3 '24 | 0 | 0 | 0 | -12M | -12M | -0.140 |
| Q2 '24 | 0 | 0 | 0 | -12M | -15M | -0.140 |
| Q1 '24 | 0 | 0 | 0 | -11M | -13M | -0.130 |
Insider Transactions View All
| Donhauser Peter D.O. filed to buy 5,000 shares at $3.6. June 17 '24 |
| Thomas Steffen filed to buy 5,000 shares at $4.5. May 17 '24 |
| MISSLING CHRISTOPHER U filed to sell 1,250,210 shares at $5.1. April 1 '24 |
| MISSLING CHRISTOPHER U filed to sell 1,018,210 shares at $8. June 30 '23 |
| Skarpelos Athanasios filed to sell 1,306,458 shares at $9.1. May 27 '22 |
Similar companies
Read more about Anavex Life Sciences (AVXL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & business outlook.
What is the Market Cap of Anavex Life Sciences?
The Market Cap of Anavex Life Sciences is $921M.
What is the current stock price of Anavex Life Sciences?
Currently, the price of one share of Anavex Life Sciences stock is $10.79.
How can I analyze the AVXL stock price chart for investment decisions?
The AVXL stock price chart above provides a comprehensive visual representation of Anavex Life Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Anavex Life Sciences shares. Our platform offers an up-to-date AVXL stock price chart, along with technical data analysis and alternative data insights.
Does AVXL offer dividends to its shareholders?
As of our latest update, Anavex Life Sciences (AVXL) does not offer dividends to its shareholders. Investors interested in Anavex Life Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Anavex Life Sciences?
Some of the similar stocks of Anavex Life Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and BridgeBio Pharma.
.